Journal of Psychiatric Insight Review

Abstract

Background: Polypharmacy with neuroleptic drugs is heavily burdened by severe, debilitating iatrogenic adverse effects, most notably drug-induced parkinsonism and the risk of fatal ventricular arrhythmias such as Torsades de Pointes. Although current clinical guidelines converge on strict diagnostic monitoring protocols, this approach remains purely reactive, merely detecting organ damage already in progress rather than preventing it. Therefore, this study evaluates an alternative therapeutic paradigm based on the principles of rational pharmacognosy, aiming to intercept cellular toxicity mechanisms early, well before the clinical manifestation of damage.

Methods & Results: Utilizing an integrated in silico approach, large-scale computational screening performed on the Caolab platform (hERG cryo-EM structure, PDB: 8ZYO) mapped the intrinsic class cardiotoxicity of antipsychotics. It revealed that common molecules such as Chlorpromazine and Olanzapine possess a higher Ligand Efficiency (LE) than the withdrawn benchmark drug Astemizole. Concurrently, to overcome the logical limitations of classical static docking on an isolated monomero, predictive multimeric modeling executed via the Boltz-1 artificial intelligence algorithm validated the amyloid nucleation dynamics of an 8-chain α-synuclein oligomer ("PTM"=0.906, "iPTM"=0.8903), delineating the pathogenic cascade along the gut-brain axis. Furthermore, multi-target profiling conducted via the chemioinformatics platform TestBio quantified—via the Tanimoto similarity coefficient (T_c)—the high structural mimicry and phytochemical convergence of Crataegus monogyna and Agrimonia eupatoria constituents toward elect pathways of inflammation (NF-κB and TNF-α inhibitors) and oxidative stress (ROS inhibitors), showing T_c medians above 0.58 and structural identity peaks equal to 1.0.

Discussion & Conclusions: Bioanalytical and literature data successfully resolve the pharmacokinetic (ADME) paradoxes of the phytocomplexes, demonstrating that: • Procyanidin B1 from Hawthorn proves cardiosafe on cultured cardiomyocytes because it is restricted in vivo to sub-threshold dosages by extensive presystemic metabolism, while advanced flexible simulations via DynamicBind prove it interacts with peripheral hotspots, leaving the channel pore completely open and unobstructed;

• Agrimoniin acts locally as a molecular wedge, sterically shielding the NAC region (residues 61–95) of α-synuclein within the jejunum, whereas its colonic metabolites (Urolithins) readily cross the blood-brain barrier (BBB) to exert direct central neuroprotection;

• Controlled activation of the vanilloid TRPV1 receptor stimulates the upregulation of the chaperone Hsp70, promoting the clearance and lysosomal degradation of pre-existing protein aggregates.

In conclusion, this study proposes the development of advanced technological drug delivery systems (nanoparticles and gastro-resistant liposomes targeted for release in the jejunum and colon), shaping an effective and safe multi target molecular barrier strategy designed to preserve the central efficacy of neuroleptic treatment while zeroing out its peripheral toxicities.